243 related articles for article (PubMed ID: 33258506)
1. Determining the prognostic significance of IKKα in prostate cancer.
Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
[TBL] [Abstract][Full Text] [Related]
2. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
Shang Z; Yu J; Sun L; Tian J; Zhu S; Zhang B; Dong Q; Jiang N; Flores-Morales A; Chang C; Niu Y
Nucleic Acids Res; 2019 May; 47(8):4211-4225. PubMed ID: 30773595
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
5. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
6. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
7. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
[TBL] [Abstract][Full Text] [Related]
8. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ
Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501
[TBL] [Abstract][Full Text] [Related]
9. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes.
Shukla S; Gupta S
Clin Cancer Res; 2004 May; 10(9):3169-78. PubMed ID: 15131058
[TBL] [Abstract][Full Text] [Related]
10. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients.
McCall P; Adams CE; Willder JM; Bennett L; Qayyum T; Orange C; Underwood MA; Edwards J
Int J Mol Sci; 2013 Aug; 14(8):16656-71. PubMed ID: 23945560
[TBL] [Abstract][Full Text] [Related]
12. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
13. NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression.
McCall P; Bennett L; Ahmad I; Mackenzie LM; Forbes IW; Leung HY; Sansom OJ; Orange C; Seywright M; Underwood MA; Edwards J
Br J Cancer; 2012 Oct; 107(9):1554-63. PubMed ID: 23093296
[TBL] [Abstract][Full Text] [Related]
14. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F
Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540
[TBL] [Abstract][Full Text] [Related]
15. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
[TBL] [Abstract][Full Text] [Related]
16. CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation.
Kuo PL; Shen KH; Hung SH; Hsu YL
Carcinogenesis; 2012 Dec; 33(12):2477-87. PubMed ID: 23027620
[TBL] [Abstract][Full Text] [Related]
17. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
